Pegaptanib: The First Anti-VEGF Agent Approved for Eyes
Ocular Peptides
2004
The year the FDA approved pegaptanib (Macugen), making it both the first anti-VEGF therapy and the first aptamer drug ever approved for clinical use in humans.
Gragoudas et al., NEJM, 2004
Gragoudas et al., NEJM, 2004
View as imageIn December 2004, the FDA approved pegaptanib sodium (brand name Macugen) for the treatment of neovascular ("wet") age-related macular degeneration, a leading cause of blindness in adults over 50. The approval carried a double distinction: pegaptanib was the first anti-VEGF (vascular endothelial growth factor) therapy approved for any indication, and it was the first aptamer, a class of synthetic oligonucleotide ligands, to reach the market as a medicine. The VISION trial, published in the New England Journal of Medicine, showed that intravitreal pegaptanib injections every six weeks reduced the risk of severe vision loss from 22% to 10% compared to sham injections (Gragoudas et al., NEJM, 2004; PMID 15625332).[1]
Pegaptanib's clinical reign was short. By 2006, ranibizumab (Lucentis) arrived with superior efficacy, and pegaptanib was eventually withdrawn from the US market. But its scientific legacy is substantial. It proved that VEGF inhibition could preserve vision in wet AMD, validated aptamers as a viable drug class, and opened the door for the anti-VEGF therapies that now represent a multi-billion-dollar category in ophthalmology. This article covers pegaptanib's mechanism, clinical data, replacement, and lasting influence on both anti-VEGF peptide treatments for wet AMD and peptide therapies for age-related macular degeneration.
Key Takeaways
- Pegaptanib (Macugen) was FDA-approved in December 2004 as the first anti-VEGF therapy and first aptamer drug for any human disease
- The 28-nucleotide PEGylated RNA aptamer binds VEGF165 with 50 picomolar affinity, specifically targeting the heparin-binding domain responsible for pathological neovascularization
- In the VISION trial (1,186 patients), 70% of those receiving 0.3 mg pegaptanib lost fewer than 15 letters of visual acuity at 54 weeks, versus 55% with sham injections (Gragoudas et al., NEJM, 2004)
- Ranibizumab (approved 2006) achieved visual acuity gains, not just stabilization, in the MARINA and ANCHOR trials, rapidly displacing pegaptanib as the standard of care
- Pegaptanib validated VEGF as a therapeutic target in wet AMD, directly enabling the development of ranibizumab, bevacizumab, aflibercept, brolucizumab, and faricimab
- Newer peptide-based anti-VEGF approaches including cell-penetrating peptide conjugates and sustained-release formulations build directly on the anti-VEGF principle pegaptanib established
What Pegaptanib Is: Anatomy of an Aptamer Drug
Pegaptanib is not a peptide in the traditional amino acid sense. It is an aptamer: a short, synthetic oligonucleotide that folds into a three-dimensional shape capable of binding a specific protein target with antibody-like affinity. The term "aptamer" derives from the Latin "aptus" (to fit) and was coined in 1990 when two independent research groups, led by Larry Gold at the University of Colorado and Jack Szostak at Harvard, independently demonstrated that nucleic acids could be evolved in vitro to bind virtually any target through a process called SELEX (Systematic Evolution of Ligands by Exponential Enrichment).
SELEX works by starting with a vast library of random oligonucleotide sequences (typically 10^14 to 10^15 unique molecules), exposing them to the target protein, recovering those that bind, amplifying them by PCR, and repeating the process for 8-15 rounds. Each round enriches the population for sequences with higher binding affinity until a small number of dominant binders emerge. The anti-VEGF aptamer that became pegaptanib was identified through SELEX screening against the VEGF165 protein in 1994, then systematically modified and truncated from its original length to the minimal 28-nucleotide sequence that retained full binding activity.
Pegaptanib consists of a 28-nucleotide single-stranded RNA molecule that has been extensively modified for pharmaceutical use. The pyrimidine nucleotides carry 2'-fluoro substitutions that protect against endonuclease degradation, while the purine nucleotides carry 2'-O-methyl modifications for additional stability. A 3'-3' deoxythymidine cap blocks exonuclease attack from the 3' end. At the 5' end, two 20-kDa polyethylene glycol (PEG) chains are attached via a lysine linker, creating a total molecular weight of approximately 50 kDa. This PEGylation serves two purposes: it extends the intravitreal half-life from hours to approximately 10 days, and it increases the hydrodynamic radius to slow diffusion out of the vitreous cavity.[1]
The aptamer folds into a specific tertiary structure that recognizes and binds the heparin-binding domain of VEGF165 with a dissociation constant (Kd) of approximately 50 picomolar. This specificity is critical to understanding pegaptanib's mechanism: it does not block all VEGF isoforms, only VEGF165.
Wet AMD: The Disease Pegaptanib Targeted
Age-related macular degeneration is the leading cause of irreversible vision loss in adults over 50 in developed countries, affecting approximately 196 million people worldwide as of 2020. The "wet" or neovascular form, while accounting for only 10-15% of all AMD cases, is responsible for approximately 90% of severe vision loss from the disease. In wet AMD, abnormal blood vessels grow from the choroid through Bruch's membrane and into the subretinal space, a process called choroidal neovascularization (CNV). Without treatment, the median time from symptom onset to legal blindness was approximately two years. These new vessels are fragile, leaky, and disorganized, leading to fluid accumulation, hemorrhage, and ultimately scarring that destroys the photoreceptors responsible for central vision.
Before pegaptanib, the treatment landscape for wet AMD was bleak. Laser photocoagulation could destroy new blood vessels but also destroyed the overlying retina, sacrificing some vision to prevent further loss. Verteporfin photodynamic therapy (Visudyne, approved 2000) offered a more selective approach using a light-activated drug to close abnormal vessels, but it too merely slowed progression rather than improving vision. Many patients progressed to legal blindness despite treatment. The understanding that VEGF drove the formation of these abnormal vessels raised hopes that targeting VEGF directly could address the underlying cause rather than just managing consequences. The molecular biology was compelling: VEGF levels in the vitreous humor of wet AMD patients were elevated compared to controls, VEGF receptors were present on choroidal endothelial cells, and animal models showed that blocking VEGF could prevent experimental choroidal neovascularization. What was missing was a drug that could reach the posterior segment of the eye and block VEGF with sufficient potency and duration to produce a clinical benefit.
Why VEGF165 Specifically?
VEGF exists in multiple splice variants: VEGF121, VEGF165, VEGF189, and VEGF206, among others. The developers of pegaptanib chose VEGF165 as the target because it was identified as the predominant pathological isoform in choroidal neovascularization. VEGF165 contains both a receptor-binding domain (shared with all isoforms) and a heparin-binding domain (absent from VEGF121) that mediates interactions with heparan sulfate proteoglycans on cell surfaces. This heparin-binding domain facilitates the formation of VEGF concentration gradients that guide new blood vessel growth toward sites of tissue ischemia.
The selectivity was initially framed as an advantage: by blocking only the pathological VEGF165 while leaving VEGF121 and other isoforms intact, pegaptanib would theoretically inhibit pathological neovascularization while preserving the physiological VEGF signaling needed for normal vascular maintenance. This hypothesis proved partially correct. Pegaptanib reduced pathological vessel growth in AMD but did not achieve the robust visual gains seen with later pan-VEGF inhibitors. In retrospect, the selective approach was too conservative. Blocking all VEGF isoforms, as ranibizumab and aflibercept do, produced substantially better clinical outcomes, suggesting that multiple VEGF isoforms contribute to the disease process in wet AMD.
The VISION Trial: First Proof of Anti-VEGF Efficacy in AMD
The VEGF Inhibition Study in Ocular Neovascularization (VISION) consisted of two concurrent, prospective, randomized, double-blind, multicenter phase 3 trials enrolling 1,186 patients with subfoveal choroidal neovascularization secondary to AMD. Patients received intravitreal injections of pegaptanib (0.3 mg, 1.0 mg, or 3.0 mg) or sham injections every six weeks for 48 weeks (Gragoudas et al., NEJM, 2004; PMID 15625332).
The primary endpoint was the proportion of patients losing fewer than 15 letters (3 lines) of visual acuity on the ETDRS chart at week 54. In the 0.3 mg group (which became the approved dose), 70% of patients met this endpoint versus 55% of sham-treated patients (p < 0.001). The risk of severe vision loss (30 letters or more) dropped from 22% in the sham group to 10% in the pegaptanib group. All three dose levels showed efficacy, with no dose-response advantage for higher doses. The development of aflibercept-loaded eye-drop hydrogels mediated by cell-penetrating peptides for corneal neovascularization represents the newest evolution of the anti-VEGF approach that pegaptanib pioneered, now seeking topical rather than intravitreal delivery.[2]
Two important limitations became apparent. First, pegaptanib primarily stabilized vision rather than improving it. Only a small minority of patients gained visual acuity. Second, the treatment required injections every six weeks for at least two years, with no clear stopping point. Third, the magnitude of benefit, while statistically significant, was modest compared to what ranibizumab would later achieve.
The safety profile was favorable relative to the invasiveness of the procedure. The most common adverse events were related to the injection procedure itself: eye pain, vitreous floaters, and punctate keratitis. Serious ocular events including endophthalmitis occurred in approximately 1% of patients per year, a rate consistent with any intravitreal injection procedure. Systemic adverse events were not significantly different between treatment and sham groups, supporting the hypothesis that isoform-selective VEGF inhibition would spare systemic vascular function.
How Ranibizumab Displaced Pegaptanib
The transition from pegaptanib to ranibizumab was swift and decisive. In June 2006, less than two years after Macugen's approval, the FDA approved ranibizumab (Lucentis), a humanized monoclonal antibody fragment that binds all active forms of VEGF-A, not just VEGF165. The MARINA trial (Rosenfeld et al., NEJM, 2006) and ANCHOR trial (Brown et al., NEJM, 2006) established that ranibizumab not only prevented vision loss but actually improved visual acuity in a substantial proportion of patients, something pegaptanib had rarely achieved.
In MARINA, 95% of ranibizumab-treated patients lost fewer than 15 letters at 12 months (compared to pegaptanib's 70%), and approximately 34% gained 15 or more letters. The visual acuity gains were maintained at 24 months. In ANCHOR, ranibizumab was compared to verteporfin photodynamic therapy (the prior standard of care) and demonstrated clear superiority, with 96% maintaining vision and 40% gaining 15 or more letters. These results represented a step-change in AMD treatment: from stabilization (pegaptanib) to improvement (ranibizumab).
The magnitude of the difference made the clinical choice straightforward. By 2007, pegaptanib prescriptions had dropped precipitously as retina specialists switched their patients to ranibizumab. Bevacizumab (Avastin), a full-length anti-VEGF antibody used off-label at approximately $50 per dose versus ranibizumab's $2,000, further eroded pegaptanib's market position. The CATT trial (Comparison of AMD Treatments Trials, 2011) demonstrated that bevacizumab was non-inferior to ranibizumab for wet AMD, making it the dominant treatment globally based on cost-effectiveness. Pegaptanib was eventually withdrawn from the US market by its manufacturer due to declining use, though it remained available in some international markets.
The competitive dynamics illustrate a broader pharmaceutical pattern. Pegaptanib was displaced not because it failed, but because it proved a concept that others could execute more effectively. The isoform-selective approach that was initially framed as pegaptanib's strength (targeting only pathological VEGF165 while preserving physiological VEGF signaling) proved to be its primary limitation. Pan-VEGF inhibition, which was initially considered potentially dangerous due to concerns about disrupting normal vascular homeostasis, turned out to be both safe and substantially more effective in the intravitreal compartment where the drug was confined.
The Anti-VEGF Revolution Pegaptanib Enabled
Despite its commercial failure, pegaptanib fundamentally changed ophthalmology. It provided the first clinical proof that VEGF inhibition could treat wet AMD, validating a therapeutic hypothesis that had been debated for over a decade. Without the VISION trial demonstrating the basic principle of intravitreal anti-VEGF therapy, the regulatory pathway for ranibizumab, bevacizumab, aflibercept (Eylea, approved 2011), brolucizumab (Beovu, approved 2019), and faricimab (Vabysmo, approved 2022) would have been substantially more uncertain. Novel antiangiogenic peptides continue to be developed for ocular neovascularization, with recent work on peptide agents for corneal neovascularization via regulation of TNF signaling pathways demonstrating that the anti-VEGF space pegaptanib opened continues to expand.[3]
The current anti-VEGF landscape now includes agents that extend treatment intervals to 16 weeks or longer, use bispecific targeting (faricimab targets both VEGF-A and angiopoietin-2), and are being formulated for sustained release through port delivery systems and implants. Research into peptide-based anti-VEGF approaches continues to build on the principle pegaptanib established. Cell-penetrating peptide conjugates have been used to deliver anti-VEGF drugs topically as eye drops, potentially eliminating the need for intravitreal injections entirely.[4] Peptide-bound aflibercept eye drops showed efficacy in a nonhuman primate model of neovascular AMD, demonstrating that peptide carriers could enable non-invasive delivery of large anti-VEGF proteins across the ocular surface.[5]
Nanoparticle-hydrogel systems for sustained release of anti-VEGF peptides represent another active research area, aiming to reduce injection frequency from monthly or bimonthly to quarterly or less.[6] Biomimetic lipoprotein nanocarriers have been engineered for noninvasive anti-VEGF delivery to the posterior segment of the eye.[7] Each of these approaches descends from the therapeutic paradigm that pegaptanib established: targeting VEGF at the site of pathological neovascularization in the eye.
For a comprehensive review of how these newer approaches compare, see our articles on anti-VEGF peptide treatments for wet AMD and peptide therapies for macular degeneration.
The GLP-1 and AMD Connection
An unexpected thread connects pegaptanib's anti-VEGF legacy to the GLP-1 receptor agonist field. Multiple recent studies have examined whether GLP-1 RAs affect AMD risk or progression. A national cohort study found that GLP-1 RA use was associated with altered risk of neovascular AMD compared to other weight loss medications.[8] A tertiary center analysis examined the impact of GLP-1 RAs on AMD outcomes in clinical practice.[9] And a preclinical study demonstrated that GLP-1 receptor agonist stimulation inhibited laser-induced choroidal neovascularization in an animal model, suggesting a potential anti-angiogenic mechanism beyond metabolic effects.[10]
These findings raise the intriguing possibility that GLP-1 receptor signaling may modulate VEGF-driven angiogenesis through pathways that pegaptanib first targeted pharmacologically. The connection remains preliminary, and the mechanisms are distinct (aptamer-mediated VEGF blockade versus receptor-mediated signaling modulation), but it illustrates how the anti-VEGF therapeutic space continues to expand in unexpected directions. A separate analysis found that AMD rates differed between patients prescribed GLP-1 RAs versus other weight loss therapies, though confounding factors make causal interpretation difficult.[11]
Pegaptanib's Legacy for Aptamer Therapeutics
Pegaptanib's approval in 2004 was expected to open a floodgate of aptamer drugs. That did not happen. For nearly two decades after Macugen, no second aptamer reached the market. The reasons were multiple: antibodies and antibody fragments proved more versatile as protein-targeting therapeutics, the patent landscape around SELEX technology created barriers, and pegaptanib's own clinical displacement by ranibizumab dampened investor enthusiasm for the aptamer platform.
The field revived in 2023 when avacincaptad pegol (Izervay) became the second aptamer to receive FDA approval, this time for geographic atrophy (dry AMD). Avacincaptad pegol targets complement factor C5, not VEGF, demonstrating that the aptamer platform could address targets beyond pegaptanib's original scope.[1] Novel aptamers targeting diverse proteins are in development, including aptamers targeting sclerostin loop3 for skeletal and muscle disorders that demonstrated improved properties without adverse cardiovascular effects.[12]
The 20th anniversary of pegaptanib's approval in 2024 prompted retrospective assessment of what the drug achieved (Bege et al., Pharmaceutics, 2025; PMID 40143057). Pegaptanib validated three concepts that remain central to nucleic acid therapeutics: that synthetic oligonucleotides can function as high-affinity protein-binding drugs, that chemical modifications can overcome the pharmacokinetic limitations of RNA, and that local delivery (intravitreal injection) can achieve therapeutic concentrations while minimizing systemic exposure. These principles now underpin not only aptamer development but also the broader nucleic acid therapeutics field, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which share the challenges of nuclease sensitivity, delivery, and pharmacokinetics that pegaptanib's developers were the first to solve in a commercially approved product.
The comparison between aptamers and peptides as protein-binding therapeutic modalities is instructive. Both can be evolved or designed to bind specific protein targets with high affinity. Aptamers are selected through SELEX, peptides through phage display or rational design. Both face pharmacokinetic challenges (rapid renal clearance, enzymatic degradation) that can be addressed through chemical modification and PEGylation. Both compete with antibodies, which offer longer half-lives and well-established manufacturing but at substantially higher molecular weights (150 kDa for an IgG versus 50 kDa for pegaptanib versus 1-5 kDa for a typical therapeutic peptide). The parallels explain why pegaptanib is covered on a peptide-focused platform: it occupies the same therapeutic niche of targeted protein modulation using a small, synthetic, chemically manufactured molecule.[1]
For other peptide-related ocular therapeutics, including those targeting dry eye disease, see our article on lacritin, the tear peptide.
Limitations of the Pegaptanib Evidence
The VISION trial, while well-designed, had limitations that became apparent in hindsight. The sham control arm received sham injections (needle placed against the sclera without penetration) rather than true placebo injections, creating a potential unmasking bias since patients and investigators could sometimes distinguish real from sham procedures. The 6-week injection interval was chosen based on pharmacokinetic modeling but was never optimized through dose-interval studies.
The decision to target only VEGF165 was based on preclinical data suggesting isoform-specific roles, but this selectivity ultimately limited efficacy. No head-to-head trial compared pegaptanib directly to ranibizumab, so the magnitude of the difference was inferred from separate trials with somewhat different patient populations and endpoints.
The withdrawal from the US market occurred due to commercial rather than safety reasons. Pegaptanib's safety record was actually favorable, with no identified systemic VEGF inhibition effects across multiple years of follow-up data. This is an advantage that the pan-VEGF inhibitors cannot claim with equal certainty: ranibizumab, aflibercept, and particularly bevacizumab have been associated with a small but non-zero risk of arterial thromboembolic events, though causality remains debated.
Whether isoform-selective VEGF inhibition has a role in specific clinical scenarios remains an open question that was never adequately studied. Patients at high cardiovascular risk, those with recent stroke or myocardial infarction, or those on concurrent systemic anti-VEGF therapy for cancer might theoretically benefit from an ocular anti-VEGF that spares systemic VEGF signaling. The complete absence of randomized trials comparing pegaptanib to ranibizumab head-to-head means this clinical question was answered by market forces rather than evidence. No pharmaceutical company had commercial incentive to fund such a trial once ranibizumab's superiority in the general AMD population was established.
The VISION trial's year-2 and year-3 extension data, while showing continued benefit for patients who remained on therapy, also revealed that many patients who crossed over from sham to active treatment showed less benefit than those who started treatment early. This "early treatment advantage" was later confirmed across the entire anti-VEGF class and influenced current clinical practice, which emphasizes prompt initiation of therapy at diagnosis rather than watchful waiting.
The Bottom Line
Pegaptanib (Macugen), FDA-approved in 2004, was the first anti-VEGF therapy and first aptamer drug approved for human use. Its 28-nucleotide PEGylated RNA aptamer selectively bound VEGF165 with 50 picomolar affinity, and the VISION trial demonstrated that intravitreal injections reduced severe vision loss from 22% to 10% in wet AMD patients. Ranibizumab displaced pegaptanib by 2006 with superior visual acuity gains. Despite its brief clinical dominance, pegaptanib validated VEGF as a therapeutic target in AMD and enabled the anti-VEGF revolution that now includes ranibizumab, aflibercept, brolucizumab, and faricimab. Newer peptide-based anti-VEGF approaches continue to build on the principle pegaptanib established.